Safety of Inclisiran: A Disproportionality Analysis from the EudraVigilance Database.

Pharmaceuticals (Basel) · 2024 · PMC11511047 · PMID 39459005

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a decreasing trendno p-value reported

The only exception was observed for the alirocumab ICSRs, which exhibited a decreasing trend of reports from the fourth to the fifth post-marketing semester.

also in 47,180 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.